<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953092</url>
  </required_header>
  <id_info>
    <org_study_id>YG1699 -01</org_study_id>
    <nct_id>NCT03953092</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Youngene Therapeutics Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Youngene Therapeutics Inc., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the
      safety, tolerability, and pharmacokinetics (PK) of YG1699 following single and multiple
      ascending oral dose administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the
      safety, tolerability, and pharmacokinetics (PK) of YG1699 following single and multiple
      ascending oral dose administration.

      The study consists of 2 parts: Part 1, SAD dose-escalation; Part 2, MAD dose-escalation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single Ascending Dose and Multiple Ascending Dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events will be evaluated</measure>
    <time_frame>76 Days</time_frame>
    <description>Safety and Tolerability of YG1699</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve [AUC]</measure>
    <time_frame>76 Days</time_frame>
    <description>area under the plasma drug concentration time curve from time 0 to T (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum plasma concentration (Cmax)</measure>
    <time_frame>76 days</time_frame>
    <description>maximum plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Diabete Mellitus</condition>
  <arm_group>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg YG1699 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg YG1699 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg YG1699 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg YG1699 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg YG1699 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg YG1699 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg YG1699 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg YG1699 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YG1699</intervention_name>
    <description>YG1699 at Multiple Doses</description>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_label>MAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_label>SAD Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebos</description>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_label>MAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_label>SAD Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Are capable of giving informed consent and complying with study procedures;

          2. Are between the ages of 18 and 55 years, inclusive;

          3. Female subjects have a negative urine pregnancy test result at screening and Day -1,
             and meet one of the following criteria:

               1. Using a medically acceptable form of birth control for at least 1 month prior to
                  screening (3 months on oral contraceptives) [e.g., hormonal contraceptives (oral,
                  patch, injectable or vaginal ring), implantable device (implantable rod or
                  intrauterine device), or a double barrier (e.g., diaphragm, cervical cap, oral,
                  patch or vaginal hormonal contraceptive, condom, spermicide, or sponge)]

               2. Surgically sterile for at least 3 months prior to screening by one of the
                  following means:

                    -  Bilateral tubal ligation

                    -  Bilateral salpingectomy (with or without oophorectomy)

                    -  Surgical hysterectomy

                    -  Bilateral oophorectomy (with or without hysterectomy)

               3. Postmenopausal, defined as the following:

                    -  Last menstrual period greater than 12 months prior to screening

                    -  Postmenopausal status confirmed by serum FSH and estradiol levels at
                       screening;

          4. Considered healthy by the Investigator, based on subject's reported medical history,
             full physical examination, clinical laboratory tests, 12-lead ECG, and vital signs;

          5. Normal renal function with estimated glomerular filtration rate (eGFR) of 60
             ml/min/1.73m2 or greater and as deemed by the Investigator;

          6. Non-smoker and no more than 2 tobacco-containing including nicotine replacement
             products in last 6 months;

          7. Body mass index (BMI) of 18.0 to 30.0 kg/m2 inclusive and body weight not less than 50
             kg;

          8. Willing and able to adhere to study restrictions and to be confined at the clinical
             research center.

          9. Male subjects with female partners of child bearing potential must agree to use
             condoms for the duration of the study and until 12 weeks after dosing with the study
             drug and must refrain from donating sperm for this same period.

        Exclusion Criteria:

          1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal,
             endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic,
             immunologic, lipid metabolism disorders, or drug hypersensitivity as determined by the
             Investigator;

          2. Known or suspected malignancy;

          3. History of pancreatitis or gall stones;

          4. History of unexplained syncope, symptomatic hypotension or hypoglycemia;

          5. Family history of long QTc syndrome;

          6. History of chronic diarrhea, malabsorption, unexplained weight loss, food allergies or
             intolerance;

          7. Poor venous access;

          8. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface
             antigen (HBsAg), or hepatitis C antibody;

          9. Donated or lost &gt;500ml of blood in the previous 3 months;

         10. Taken an investigational drug or participated in a clinical trial within 3 months (or
             5 half-lives), whichever is longer;

         11. Taken any prescription medications within 14 days or 5 half-lives (whichever is
             longer) of the first dose of study drug;

         12. Hospital admission or major surgery within 6 months prior to screening;

         13. A history of prescription drug abuse, or illicit drug use within 9 months prior to
             screening;

         14. A history of alcohol abuse according to medical history within 9 months prior to
             screening;

         15. A positive screen for alcohol, drugs of abuse at screening or Day -1;

         16. An unwillingness or inability to comply with food and beverage restrictions during
             study participation;

         17. Use of over-the-counter (OTC) medication within 7 days, and herbal (including St
             John's Wort, herbal teas, garlic extracts) within 7 days prior to dosing (Note: Use of
             acetaminophen at &lt; 2 g/day is permitted until 24 hours prior to dosing);

         18. Any condition or finding that in the Investigators opinion would put the subject or
             study conduct at risk if the subject were to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yalin Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Youngene Therapeutics Inc., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annie Li, Pharm D</last_name>
    <phone>201-416-7770</phone>
    <email>ali@frontagelab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Frontage Labs</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Li, PharmD</last_name>
      <phone>201-416-7770</phone>
      <email>ali@frontagelab.com</email>
    </contact>
    <investigator>
      <last_name>Frank Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

